Veterans Affairs Medical Center, Washington, District of Columbia.
George Washington University School of Medicine and Health Sciences, Washington, District of Columbia.
J Gerontol A Biol Sci Med Sci. 2019 Nov 13;74(12):1916-1921. doi: 10.1093/gerona/glz045.
Antipsychotics are prescribed to treat various symptoms in older adults, however, their safety in this context has not been fully evaluated. The objective was to evaluate mortality risks associated with off-label use of antipsychotics among older adults with no preexisting mental illness or dementia relative to those with diagnosis of dementia.
Data (2007-2015) were derived from Department of Veterans Affairs registries for 730,226 patients (≥65 years) with no baseline serious mental illness, dementia). We estimated the cumulative incidence of antipsychotics prescription and 10-year all-cause mortality. The extended Cox models were used to estimate Hazard Ratios (HRs) associated with antipsychotics prescription, adjusted for time-varying covariates, dementia diagnosis, comorbidity index score, and age at time of first exposure to antipsychotics.
The study included 98% males, 13% African Americans, and 81% Caucasian. Patients with dementia and antipsychotics had the highest risk of mortality (78.0%), followed by (73.0%) for patients with dementia alone and compared with patients without dementia or antipsychotics exposure who had the lowest mortality risk (42.0%). Exposure to typical antipsychotics was associated with (HR: 2.1, confidence interval [CI] 2.0-2.2) compared with atypical antipsychotics (HR: 1.5, CI 1.4-1.5, p = <.0001).
In a large cohort of older adults, antipsychotics were associated with an increased risk of all-cause mortality. While significant increase in mortality was attributable to the diagnosis of dementia, the addition of antipsychotics resulted in added mortality risk among all patients. Antipsychotic medications should be used cautiously in all older adults, not only those with dementia.
抗精神病药被用于治疗老年人的各种症状,但它们在这种情况下的安全性尚未得到充分评估。本研究旨在评估与诊断为痴呆症的患者相比,无先前精神疾病或痴呆症的老年患者使用非适应证抗精神病药的死亡率风险。
数据来源于退伍军人事务部的登记处(2007-2015 年),涉及 730226 名(≥65 岁)无基线严重精神疾病或痴呆症的患者。我们估计了抗精神病药处方的累积发生率和 10 年全因死亡率。使用扩展 Cox 模型来估计与抗精神病药处方相关的风险比(HRs),并根据时间变化的协变量、痴呆诊断、合并症指数评分和首次暴露于抗精神病药时的年龄进行调整。
研究包括 98%的男性、13%的非裔美国人和 81%的白人。患有痴呆症和抗精神病药的患者死亡率风险最高(78.0%),其次是仅患有痴呆症的患者(73.0%),而无痴呆症或抗精神病药暴露的患者死亡率风险最低(42.0%)。与使用非典型抗精神病药相比,使用典型抗精神病药与死亡率风险增加相关(HR:2.1,95%置信区间[CI]:2.0-2.2)(HR:1.5,CI:1.4-1.5,p<.0001)。
在一项大型老年患者队列中,抗精神病药与全因死亡率风险增加相关。虽然死亡率的显著增加归因于痴呆症的诊断,但在所有患者中,添加抗精神病药会导致额外的死亡率风险。抗精神病药物应谨慎用于所有老年人,而不仅仅是痴呆症患者。